MODY, cystic fibrosis, and Wolfram syndrome all have something in common. Believe it or not, they are all a form of diabetes. This week, our Clinical Text from the Handbook of Diabetes looks at these and other types or non-traditional causes of diabetes. Our Homerun Slides focus on how to …

Diabetes is a huge and growing problem, and the costs to society are high and escalating. In the Middle East and North Africa, 1 in 10 adults has diabetes. The Top 5 countries for prevalence in this region are: Saudi Arabia, Kuwait, Qatar, bahrain, and the united Arab Emirates. To …

Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP   Maturity-onset diabetes of the young Maturity-onset diabetes of the young (MODY) owes its name to a time when diabetes was defined by age of onset. The nomenclature has stuck, however, and MODY defines usually non-insulin dependent diabetes occurring before the age …

Recently JARDIANCE (Empagliflozin) was approved for use, making it the third in this new class of medications. The first two, Invokana (canagiflozin) and Farxiga (dapagliflozin), have had relatively good acceptance into the marketplace especially with the financial ease they have established to get patients to use the medication. There are …

It is always interesting when two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes. Our own advisory board endocrinologist, Stanley Schwartz, is a good …

It is always interesting when you two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes. I had the opportunity to review a conversation that John …

  Sanofi is expanding its insulin portfolio to include the new inhaled insulin, Affreza. While it may not perform in the market at the scale of Lantus, I, for one, am glad that Sanofi is doing this. Five years ago a small company called VeroScience came out with a new …

First SGLT-2 + Metformin Approved See this week’s Item #1.

  PreDiabetes Screening Test  Finally there’s a test that only focuses on PreDiabetes. At the recent AADE meeting, a new company came our way with a home laboratory test that can demonstrate whether a patient has prediabetes or even diabetes. It’s a mail-away finger-stick test that is 99.9% accurate. Now you can …

MannKind will get 35% of the profits while Sanofi is set to get 65% of profits on Afrezza. Afrezza was approved with a black box warning which states, "Acute bronchospasm has been observed in patients with asthma and COPD using Afrezza. Afrezza is contraindicated in patients with chronic lung disease such as asthma …